Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Novo Nordisk A/S (NVONy)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Novo Nordisk ADR historical data, for real-time data please try another search
60.5000 0.0000    0.00%
22/03 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US6701002056 
  • Volume: 0
  • Bid/Ask: 59.0000 / 60.5000
  • Day's Range: 60.0000 - 60.5000
Novo Nordisk ADR 60.5000 0.0000 0.00%

NVONy Ratios

 
Assess the performance of Novo Nordisk ADR (NVO). This table contains core financial ratios such as Price-to-Earnings (P/E ratio), Return-On-Investment (ROI), Earnings per share (EPS), Dividend yield and others based on Novo Nordisk A/S's latest financial reports. Compare the performance metrics of Novo Nordisk ADR (NVO) against the industry averages.
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM - 19.61
Price to Sales TTM - 2.82
Price to Cash Flow MRQ - 18.81
Price to Free Cash Flow TTM - 22.23
Price to Book MRQ - 2.37
Price to Tangible Book MRQ - 79.38
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM 84.6% 62.23
Gross Margin 5YA - 63.07
Operating margin TTM - 22.83
Operating margin 5YA - 16.99
Pretax margin TTM - 16.51
Pretax margin 5YA - 7.69
Net Profit margin TTM - 13.35
Net Profit margin 5YA - 9.95
   
Revenue/Share TTM - 50.36
Basic EPS ANN 18.67 4.64
Diluted EPS ANN 18.62 4.64
Book Value/Share MRQ - 55.87
Tangible Book Value/Share MRQ 10.35 -10.5
Cash/Share MRQ - 3.99
Cash Flow/Share TTM - 8.81
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM - 13.73
Return on Equity 5YA - 5.77
Return on Assets TTM - 5.95
Return on Assets 5YA - 4.19
Return on Investment TTM - 10.96
Return on Investment 5YA - 7.54
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 63.15% 228.15
EPS(TTM) vs TTM 1 Yr. Ago TTM 52.32% 1,247.78
5 Year EPS Growth 5YA - -3.25
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 36.95% 16.19
Sales (TTM) vs TTM 1 Yr. Ago TTM 31.26% 14.95
5 Year Sales Growth 5YA - 5.24
5 Year Capital Spending Growth 5YA - 5.1
   
Quick Ratio MRQ - 0.65
Current Ratio MRQ 0.82 1.29
LT Debt to Equity MRQ - 56.7
Total Debt to Equity MRQ - 66.67
Efficiency    
Asset Turnover TTM 0.84 0.44
Inventory Turnover TTM - 1.79
Revenue/Employee TTM - 399.66K
Net Income/Employee TTM - 51.33K
Receivable Turnover TTM 4.49 4.48
   
Dividend Yield ANN - 2.12
Dividend Yield 5 Year Avg. 5YA - 2.52
Dividend Growth Rate ANN - -6.71
Payout Ratio TTM 37.96% 33.43
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

NVO Comments

Write your thoughts about Novo Nordisk DRC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
yeongjin white
yeongjin white Mar 14, 2024 11:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
300 by 2024
Reply
6 0
Report
roy reyes
roy reyes Feb 05, 2024 8:07PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
gonna dominate the obesity space with Catalent mreger
Reply
2 0
Report
Karsten Vester
Karsten Vester Feb 01, 2024 4:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
450 by 2030.. Serving 1 mill custumors now and there are 800 mill. U do the math..
Reply
7 0
Report
D Petersen
D Petersen Jan 29, 2024 8:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
NVO should advance nicely Wednesday on good earnings and a bright 2024 outlook.
Reply
2 1
Report
Karsten Vester
Karsten Vester Nov 28, 2023 9:52AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Eli is very keen on disrupting NN but they dont even have cardio vascular studies or a candidate for next generation but NN dos. They are way behind so dont be disrupted by their lobby activities ….
Reply
4 3
Report
In the Money
In the Money Oct 21, 2023 7:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
140+ eoy
Reply
4 1
Report
Paul Chan
Paul Chan Oct 21, 2023 7:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Not with the recent deaths from Ozempic.
Reply
0 3
Report
Karsten Vester
Karsten Vester Oct 21, 2023 7:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Come with dome documentstion dude. Far out to say
Reply
0 0
Report
dar dar
dar dar Oct 13, 2023 12:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
like all things, eventually we will know the outcome
Reply
0 2
Report
Karsten Vester
Karsten Vester Oct 03, 2023 11:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Now all small investors seems to fanzy ophra Winfrey to dictate the benefits and dowfalls in pharma industry. What a world with celebraties and you tupers now rules the world. S… t.. f… up woman - you dont know what you are talking about and go back to girlish problems and your billions..
Reply
1 1
Report
Roelant
Roelant Sep 30, 2023 4:04AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
But, pharma boys and girls can only continue parabolic if sick and overweight people increase....dilemma.
Reply
0 0
Report
Mesna Kroglica
Mesna Kroglica Sep 16, 2023 7:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Something is not right here. There are probably alot of long term side effects to using ozempic for weight loss, the drug was intended to treat diabetes not weight loss keep that in mind. And we all know that taking drugs if you are healty is dangerous.
Reply
2 0
Report
Karsten Vester
Karsten Vester Sep 16, 2023 7:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
It has been testet for many years for diabetics and this is a known "side effect" (weight loss) and it seems as if this in fact is a wonder druck so no need to say bad things without knowing anything about it. Take into accoutn how many problems there are with peoples weight in this world. If we can stop people from eating as much and loose weight I cannot even begin to tell you how many lifestyle problems we wont have anymore.
Reply
2 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email